US EditionPublished • loading... • Updated
Early clinical results deliver encouraging milestone for malaria drug candidate
Summary by Medical Xpress
1 Articles
1 Articles
Early clinical results deliver encouraging milestone for malaria drug candidate
Findings from two early clinical studies suggest a new dual-action antimalarial drug candidate is well tolerated in humans. The first-in-class clinical candidate, MK7602, is being developed by WEHI and global biopharmaceutical company MSD (tradename of Merck & Co., Inc., Rahway, N.J., U.S.).
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
